Drug agency Dr Reddy”s Laboratories on Tuesday mentioned it has launched Minoxidil topical answer for the therapy of feminine sample hair loss in India.
The corporate has launched prescription drug Minoxidil topical answer USP 2 per cent and 5 per cent for the therapy of feminine sample hair loss. The corporate will promote its merchandise below the model names Mintop 2 per cent and Mintop Eva 5 per cent, respectively, Dr Reddy”s mentioned in a regulatory submitting.
The launch follows the first-ever approval of the extra indication by the Central Medication Commonplace Management Organisation (COSCO) in India for the usage of the product for the therapy of feminine sample hair loss (FPHL), it added.
Minoxidil topical answer has been authorised in India for the therapy of alopecia in males (male sample baldness), the submitting mentioned.
“This marks the first-ever approval given to a first-line therapy possibility for feminine sample hair loss, and actually fulfils a hitherto unmet want,” Dr Reddy”s Laboratories CEO (Branded Markets- India and Rising Markets) M V Ramana mentioned.
The corporate”s Minoxidil topical answer for ladies will probably be broadly out there within the nation, and thru this launch, “we hope to convey aid and luxury to sufferers identified with FPHL in India”, he added.
Shares of Dr Reddy”s Laboratories on Tuesday fell 0.82 per cent to shut at Rs 4,875 per scrip on the BSE.